Cost‐Effectiveness of Daptomycin versus Vancomycin and Gentamicin for Patients with Methicillin‐ResistantStaphylococcus aureusBacteremia and/or Endocarditis | Zendy

Sujata M. Bhavnani | Zendy; A. Prakhya | Zendy; Jeffrey Hammel | Zendy; Paul G. Ambrose | Zendy

Open Access

Cost‐Effectiveness of Daptomycin versus Vancomycin and Gentamicin for Patients with Methicillin‐ResistantStaphylococcus aureusBacteremia and/or Endocarditis

Author(s) -

Sujata M. Bhavnani,

A. Prakhya,

Jeffrey Hammel,

Paul G. Ambrose

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/604710

Subject(s) - daptomycin , medicine , bacteremia , vancomycin , endocarditis , gentamicin , staphylococcus aureus , methicillin resistant staphylococcus aureus , staphylococcal infections , antibiotics , microbiology and biotechnology , surgery , bacteria , genetics , biology

Methicillin-resistant Staphylococcus aureus (MRSA) is an increasingly common cause of bacteremia and endocarditis. The cost-effectiveness (CE) of daptomycin was compared with that of vancomycin-gentamicin in patients with MRSA bacteremia with or without endocarditis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research